Cargando…

Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries

BACKGROUND: Defects in the RYR1 (OMIM#180901) gene lead to Ryanodine receptor type 1‐related myopathies (RYR1‐RM); the most common subgroup of congenital myopathies. METHODS: Congenital myopathy presents a diagnostic challenge due to the need for multiple testing modalities to identify the many diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Shillington, Amelle, Zea Vera, Alonso, Perry, Tanya, Hopkin, Robert, Thomas, Cameron, Cooper, David, Suhrie, Kristen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580091/
https://www.ncbi.nlm.nih.gov/pubmed/34528764
http://dx.doi.org/10.1002/mgg3.1804
_version_ 1784596544756908032
author Shillington, Amelle
Zea Vera, Alonso
Perry, Tanya
Hopkin, Robert
Thomas, Cameron
Cooper, David
Suhrie, Kristen
author_facet Shillington, Amelle
Zea Vera, Alonso
Perry, Tanya
Hopkin, Robert
Thomas, Cameron
Cooper, David
Suhrie, Kristen
author_sort Shillington, Amelle
collection PubMed
description BACKGROUND: Defects in the RYR1 (OMIM#180901) gene lead to Ryanodine receptor type 1‐related myopathies (RYR1‐RM); the most common subgroup of congenital myopathies. METHODS: Congenital myopathy presents a diagnostic challenge due to the need for multiple testing modalities to identify the many different genetic etiologies. In this case, the patient remained undiagnosed after whole‐exome sequencing (WES), chromosomal microarray, methylation analysis, targeted deletion and duplication studies, and targeted repeat expansion studies. Clinical whole‐genome sequencing (WGS) was then pursued as part of a research study to identify a diagnosis. RESULTS: WGS identified compound heterozygous RYR1 intronic variants, RNA sequencing confirmed both variants to be pathogenic causing RYR1‐RM in a phenotype of severe congenital hypotonia with respiratory failure from birth, neonatal brain hemorrhage, and congenital heart disease involving transposition of the great arteries. CONCLUSION: While there is an ongoing debate about the clinical superiority of WGS versus WES for patients with a suspected genetic condition, this scenario highlights a weakness of WES as well as the added cost and delay in diagnosis timing with having WGS follow WES or even ending further genetic testing with a negative WES. While knowledge gaps still exist for many intronic variants, transcriptome analysis provides a way of validating the resulting dysfunction caused by these variants and thus allowing for appropriate pathogenicity classification. This is the second published case report of a patient with pathogenic intronic variants in RYR1‐RM, with clinical RNA testing confirming variant pathogenicity and therefore the diagnosis suggesting that for some patients careful analysis of a patient's genome and transcriptome are required for a complete genetic evaluation. The diagnostic odyssey experienced by this patient highlights the importance of early, rapid WGS.
format Online
Article
Text
id pubmed-8580091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85800912021-11-17 Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries Shillington, Amelle Zea Vera, Alonso Perry, Tanya Hopkin, Robert Thomas, Cameron Cooper, David Suhrie, Kristen Mol Genet Genomic Med Clinical Reports BACKGROUND: Defects in the RYR1 (OMIM#180901) gene lead to Ryanodine receptor type 1‐related myopathies (RYR1‐RM); the most common subgroup of congenital myopathies. METHODS: Congenital myopathy presents a diagnostic challenge due to the need for multiple testing modalities to identify the many different genetic etiologies. In this case, the patient remained undiagnosed after whole‐exome sequencing (WES), chromosomal microarray, methylation analysis, targeted deletion and duplication studies, and targeted repeat expansion studies. Clinical whole‐genome sequencing (WGS) was then pursued as part of a research study to identify a diagnosis. RESULTS: WGS identified compound heterozygous RYR1 intronic variants, RNA sequencing confirmed both variants to be pathogenic causing RYR1‐RM in a phenotype of severe congenital hypotonia with respiratory failure from birth, neonatal brain hemorrhage, and congenital heart disease involving transposition of the great arteries. CONCLUSION: While there is an ongoing debate about the clinical superiority of WGS versus WES for patients with a suspected genetic condition, this scenario highlights a weakness of WES as well as the added cost and delay in diagnosis timing with having WGS follow WES or even ending further genetic testing with a negative WES. While knowledge gaps still exist for many intronic variants, transcriptome analysis provides a way of validating the resulting dysfunction caused by these variants and thus allowing for appropriate pathogenicity classification. This is the second published case report of a patient with pathogenic intronic variants in RYR1‐RM, with clinical RNA testing confirming variant pathogenicity and therefore the diagnosis suggesting that for some patients careful analysis of a patient's genome and transcriptome are required for a complete genetic evaluation. The diagnostic odyssey experienced by this patient highlights the importance of early, rapid WGS. John Wiley and Sons Inc. 2021-09-16 /pmc/articles/PMC8580091/ /pubmed/34528764 http://dx.doi.org/10.1002/mgg3.1804 Text en © 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Reports
Shillington, Amelle
Zea Vera, Alonso
Perry, Tanya
Hopkin, Robert
Thomas, Cameron
Cooper, David
Suhrie, Kristen
Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
title Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
title_full Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
title_fullStr Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
title_full_unstemmed Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
title_short Clinical RNA sequencing confirms compound heterozygous intronic variants in RYR1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
title_sort clinical rna sequencing confirms compound heterozygous intronic variants in ryr1 in a patient with congenital myopathy, respiratory failure, neonatal brain hemorrhage, and d‐transposition of the great arteries
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580091/
https://www.ncbi.nlm.nih.gov/pubmed/34528764
http://dx.doi.org/10.1002/mgg3.1804
work_keys_str_mv AT shillingtonamelle clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries
AT zeaveraalonso clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries
AT perrytanya clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries
AT hopkinrobert clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries
AT thomascameron clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries
AT cooperdavid clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries
AT suhriekristen clinicalrnasequencingconfirmscompoundheterozygousintronicvariantsinryr1inapatientwithcongenitalmyopathyrespiratoryfailureneonatalbrainhemorrhageanddtranspositionofthegreatarteries